Top Drugs To Watch At ASH 2017: CAR-T, Venetoclax Among Highlights
• By Emily Hayes
Phase III data for J&J's Darzalex in frontline multiple myeloma will be a highlight of a late-breaker session at the ASH meeting. Above, 3D rendering of the CD38 (ectodomain fragment) enzyme, the target of Darzalex.
Keep up with the top pharma business news of the week. On the go.
